0.5% More Ani Pharmaceuticals Inc (NASDAQ:ANIP) Shares Shorted

May 16, 2018 - By Carolyn Hewitt

During 2017 Q4 the big money sentiment decreased to 1.09. That’s change of 0.60, from 2017Q3’s 1.69. 13 investors sold all, 43 reduced holdings as ANI Pharmaceuticals, Inc. ratio turned negative. 38 rose holdings while 23 funds took holdings. Funds hold 6.25 million shares thus 0.89% less from 2017Q3’s 6.31 million shares.
The Connecticut-based Matarin Capital Mgmt Ltd has invested 0.07% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Thomson Horstmann And Bryant Incorporated accumulated 20,101 shs. Georgia-based Invesco has invested 0.01% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Alliancebernstein L P reported 20,288 shs. Guggenheim holds 0.01% or 43,691 shs. Driehaus Capital Mgmt Ltd Liability Co invested in 3,414 shs. 61,412 were reported by Counselors Of Maryland Lc. Ameriprise Financial Incorporated reported 0% stake. Etrade Capital Mngmt Ltd reported 23,832 shs. Great West Life Assurance Can reported 12,614 shs. The Idaho-based Caprock Group has invested 0.06% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). The Georgia-based Cornercap Investment Counsel has invested 0.1% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Fifth Third Financial Bank holds 8,673 shs or 0% of its capital. Ls Inv Advisors Ltd reported 1,704 shs. Bank & Trust Of Montreal Can holds 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) or 2,408 shs.

ANI Pharmaceuticals, Inc. registered $15.78 million net activity with 0 buys and 9 insider sales since March 1, 2018. $1.74 million worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was sold by RAYNOR DANIEL. $3.87M worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was sold by MARSHBANKS TRACY. $1.77 million worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was sold by Schrepfer Robert W. On Monday, March 5 Marken James G. also sold $258,640 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Ani Pharmaceuticals Inc (NASDAQ:ANIP) recorded an increase of 0.5% in shares shorted. FINRA issued in May ANIP’s total 688,400 shares shorted. Previously was reported up change of 0.5% from 685,000 shares. Previous ANIP’s position will need 11 days to restore. It has 65,700 average volume. Ani Pharmaceuticals Inc float short is 7.7%.

The stock increased 0.38% or $0.235 during the last trading session, reaching $62.205.Currently ANI Pharmaceuticals, Inc. is uptrending after 18.93% change in last May 16, 2017. ANIP has 47,324 shares volume. ANIP outperformed the S&P 500 by 7.38%.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States.The firm is worth $733.17 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations.Last it reported negative earnings. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

A couple more ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were announced by: Streetinsider.com which released on April 29, 2018 “ANI Pharma (ANIP) Agrees to Acquire Generic Products & Other Assets from Amneal Pharmaceuticals LLC and Impax …”, also Seekingalpha.com on April 27, 2018 announced “ANI Pharmaceuticals buying assets from Amneal, Impax”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” on May 08, 2018. Globenewswire.com has article titled “Market Trends Toward New Normal in Viacom, Nutanix, ANI Pharmaceuticals, PACCAR, Cabot Oil & Gas, and Box …”.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.